anti-PD-1/PD-L1 antibody

DRUG2 trials

Sponsors

Shanghai Zhongshan Hospital, Hangzhou Sumgen Biotech Co., Ltd.

Conditions

Advanced Solid TumorsCholangiocarcinoma

Phase 1

An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors

Not yet recruitingNCT07774611

Hangzhou Sumgen Biotech Co., Ltd.Advanced Solid Tumors

Start: 2026-09-22End: 2028-12-31Target: 180Updated: 2026-08-19

Unknown Phase

Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA

RecruitingNCT07291063

Shanghai Zhongshan HospitalCholangiocarcinoma

Start: 2024-07-19End: 2029-12-31Target: 50Updated: 2025-12-18